MX388989B - Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica. - Google Patents

Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.

Info

Publication number
MX388989B
MX388989B MX2017008904A MX2017008904A MX388989B MX 388989 B MX388989 B MX 388989B MX 2017008904 A MX2017008904 A MX 2017008904A MX 2017008904 A MX2017008904 A MX 2017008904A MX 388989 B MX388989 B MX 388989B
Authority
MX
Mexico
Prior art keywords
artery disease
coronary artery
diagnostics
blood
atherosclerotic coronary
Prior art date
Application number
MX2017008904A
Other languages
English (en)
Other versions
MX2017008904A (es
Inventor
Bradley O Brown
Idean B Marvasty
Szilard Voros
Original Assignee
Global Genomics Group Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Genomics Group Llc filed Critical Global Genomics Group Llc
Publication of MX2017008904A publication Critical patent/MX2017008904A/es
Publication of MX388989B publication Critical patent/MX388989B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ecology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

La invención, en algunos aspectos, se relaciona con métodos para evaluar a un sujeto humano para determinar si presenta enfermedad de arteria coronaria ateroesclerótica (ASCAD) o si tiene una placa ateroesclerótica coronaria. En algunos aspectos, la invención se relaciona con métodos y kits útiles para diagnosticar, clasificar, caracterizar y tratar CAD ateroesclerótica y/o una placa ateroesclerótica coronaria.
MX2017008904A 2015-01-09 2016-01-08 Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica. MX388989B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101445P 2015-01-09 2015-01-09
PCT/US2016/012725 WO2016112337A1 (en) 2015-01-09 2016-01-08 Blood based biomarkers for diagnosing atherosclerotic coronary artery disease

Publications (2)

Publication Number Publication Date
MX2017008904A MX2017008904A (es) 2018-02-09
MX388989B true MX388989B (es) 2025-03-11

Family

ID=56356500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008904A MX388989B (es) 2015-01-09 2016-01-08 Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.

Country Status (12)

Country Link
US (2) US10254272B2 (es)
EP (3) EP3967217B1 (es)
KR (1) KR20170102983A (es)
CN (2) CN107427221B (es)
CA (1) CA2973116C (es)
HU (3) HUE056203T2 (es)
IL (1) IL253179A0 (es)
MX (1) MX388989B (es)
SG (1) SG11201705444QA (es)
TW (2) TWI610079B (es)
WO (1) WO2016112337A1 (es)
ZA (1) ZA201705032B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388989B (es) * 2015-01-09 2025-03-11 Global Genomics Group Llc Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
CN107491656B (zh) * 2017-09-04 2020-01-14 北京航空航天大学 一种基于相对危险度决策树模型的妊娠结局影响因子评估方法
US11513131B2 (en) * 2018-01-22 2022-11-29 Global Genomics Group, LLC Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof
WO2019173709A1 (en) * 2018-03-09 2019-09-12 Nearing Bruce D High throughput ecg heterogeneity assessment to determine presence of coronary artery stenosis
CN111919120A (zh) * 2018-03-29 2020-11-10 学校法人庆应义塾 包含伊立替康的抗癌剂疗法的敏感性判定标志物
US11036779B2 (en) * 2018-04-23 2021-06-15 Verso Biosciences, Inc. Data analytics systems and methods
CN109060977B (zh) * 2018-07-13 2024-07-02 深圳市绘云生物科技有限公司 用于肝纤维化和肝硬化诊断的生物标志物和试剂盒及使用方法
CN109164183A (zh) * 2018-09-29 2019-01-08 中国检验检疫科学研究院 肝脏损伤相关差异性内源性标志物及其筛选方法和应用
CN110487922B (zh) * 2018-12-17 2022-09-27 广西中烟工业有限责任公司 一种烟叶中苏糖酸和苏糖酸酯的gc-ms分析方法
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
KR102177280B1 (ko) * 2019-05-09 2020-11-10 고려대학교 세종산학협력단 호모시스테인 설핀산 또는 시스테인산을 포함하는 급성심근경색 진단용 바이오마커 조성물
CN111505131B (zh) * 2020-01-02 2023-03-31 东莞东华医院有限公司 基于血清代谢组学改变建立的预测冠心病斑块不稳定性临床模型
US20220392065A1 (en) * 2020-01-07 2022-12-08 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
EP3865591B1 (en) * 2020-02-14 2024-04-03 Cardiomix S.r.l. Set of biomarkers for the diagnosis of brugada syndrome
CN111983160B (zh) * 2020-08-14 2022-08-09 中元伯瑞生物科技(珠海横琴)有限公司 神经酸在治疗脑卒中药物中的应用
US20240079145A1 (en) * 2021-01-15 2024-03-07 My Lua Llc Systems and methods for deriving health indicators from user-generated content
CN114938659B (zh) * 2021-02-05 2025-03-04 中国医学科学院阜外医院 基于代谢组学数据的心血管病发病风险评估标志物及应用
CN113484453B (zh) * 2021-07-07 2022-08-09 天津中医药大学 一种缺血性脑卒中预警方法
CN113777203A (zh) * 2021-07-21 2021-12-10 嘉兴学院 二甲基甘氨酸作为胎儿先天性心脏病血清标志物的应用
CN114324641A (zh) * 2021-12-22 2022-04-12 山东英盛生物技术有限公司 一种冠心病代谢标志物及在诊断、预后方面的应用
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
CN114705782B (zh) * 2022-04-07 2023-12-01 中国人民解放军总医院第一医学中心 用于诊断或监测结直肠癌的血浆代谢标志物组合及应用
CN116338052B (zh) * 2023-04-06 2025-05-02 安徽盈科生物科技有限公司 一种o-磺基-l-酪氨酸钠盐及其有关物质的高效液相色谱分析方法
WO2025002914A1 (en) 2023-06-26 2025-01-02 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Antagonists of the imidazoline-1 receptor for use in the prevention and/or treatment of an autoinflammatory or autoimmune disease
CN117110627B (zh) * 2023-10-18 2024-01-09 天津云检医学检验所有限公司 用于新生儿干血斑先天性心脏病及其亚型评估的标志物
CN117405870B (zh) * 2023-12-15 2024-03-19 北京市心肺血管疾病研究所 基于血清脂质代谢物构建冠心病患者不稳定斑块表型的预测模型
TWI859033B (zh) * 2023-12-18 2024-10-11 安益藥業股份有限公司 一種診斷犬科動物胰臟炎的方法與試劑組與一種使用醯基肉鹼作為診斷犬科動物胰臟炎之用途
CN118010893B (zh) * 2024-04-09 2024-07-23 北京市心肺血管疾病研究所 类花生酸在用于评估急性冠脉综合征患者血运重建术后发生不良心血管事件风险中的应用
CN118897028B (zh) * 2024-07-17 2025-03-28 查理高特(青岛)健康科技有限公司 一种用于预测痛风发作风险的生物标志物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666881B1 (en) * 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
US8321154B2 (en) 2007-03-26 2012-11-27 Bg Medicine, Inc. Methods for detecting coronary artery disease
US20110021468A1 (en) * 2007-07-03 2011-01-27 Joslin Diabetes Center, Inc. Treatment of cardiovascular disease with salicylates
MX2010000414A (es) * 2007-07-17 2010-04-01 Metabolon Inc Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos.
AU2010281524A1 (en) * 2009-08-06 2012-02-23 Neuraltus Pharmaceuticals, Inc. Treatment of macrophage-related disorders
CN102884435A (zh) * 2009-11-27 2013-01-16 贝克Idi心脏和糖尿病研究院控股有限公司 用于稳定和不稳定心脏病的脂质生物标记物
AU2011223789A1 (en) * 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
DK2385374T4 (en) 2010-05-05 2018-04-30 Zora Biosciences Oy LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
NZ707637A (en) * 2010-07-19 2016-09-30 Otago Innovation Ltd Signal biomarkers
US9428749B2 (en) * 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
CN105008931A (zh) * 2013-03-08 2015-10-28 佐拉生物科学公司 非高密度脂蛋白来源的cvd标志物
BR112015028253A2 (pt) * 2013-05-14 2017-07-25 Metabolon Inc biomarcadores relacionados à função renal e métodos para utilização dos mesmos
WO2015157407A1 (en) * 2014-04-08 2015-10-15 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
WO2016073547A1 (en) * 2014-11-05 2016-05-12 Metabolon, Inc. System, method and apparatus for determining the effect of genetic variants
MX388989B (es) * 2015-01-09 2025-03-11 Global Genomics Group Llc Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.

Also Published As

Publication number Publication date
TWI690707B (zh) 2020-04-11
US20160202239A1 (en) 2016-07-14
EP3967217A1 (en) 2022-03-16
CN107427221A (zh) 2017-12-01
US20190391131A1 (en) 2019-12-26
CN107427221B (zh) 2021-03-09
CA2973116A1 (en) 2016-07-14
TW201802471A (zh) 2018-01-16
CA2973116C (en) 2023-08-15
ZA201705032B (en) 2019-09-25
MX2017008904A (es) 2018-02-09
EP3650852A1 (en) 2020-05-13
US10254272B2 (en) 2019-04-09
TW201725387A (zh) 2017-07-16
EP3242588B1 (en) 2019-10-16
EP3967217B1 (en) 2024-08-14
TWI610079B (zh) 2018-01-01
CN113156096A (zh) 2021-07-23
EP3242588A1 (en) 2017-11-15
HUE056203T2 (hu) 2022-01-28
EP3242588A4 (en) 2018-10-17
HUE047951T2 (hu) 2020-05-28
KR20170102983A (ko) 2017-09-12
WO2016112337A1 (en) 2016-07-14
EP3650852B1 (en) 2021-08-18
HUE069048T2 (hu) 2025-02-28
IL253179A0 (en) 2017-08-31
EP3967217C0 (en) 2024-08-14
SG11201705444QA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
MX388989B (es) Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.
EA201270020A1 (ru) Определение риска развития атеросклеротической болезни сердца
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
CR20170133A (es) Análisis de coagulación universal microfluídico basado en chips
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
BR112014031365A2 (pt) métodos de detectar doenças ou condições
MX2015015561A (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
WO2012122374A3 (en) Non-invasive methods for diagnosing chronic organ transplant rejection
EP3411720A4 (en) DIAGNOSIS AND PROGNOSIS PROCEDURE FOR HEART CIRCULAR DISEASES AND EVENTS
PL3923971T3 (pl) Analizowanie wpływu polirybonukleotydu na ciliogenezę
HK1247250A1 (zh) 用於指导癌症治疗的内容相关的诊断测试
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2015034886A3 (en) Wellness panel for companion animals
MX375421B (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
WO2015164747A8 (en) Methods for diagnosing celiac disease using circulating cytokines/chemokines
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
NZ729773A (en) Biomarkers for disease progression in melanoma
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
MX2016008045A (es) Biomarcadores de lipogenesis de novo y metodos de uso de los mismos.
EP3374026A4 (en) THROMBOZYTE BIOMARKERS AND DIAGNOSTIC METHODS FOR VASCULAR DISEASES
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
GB2552271A (en) A method for diagnosing lung cancer
MX363679B (es) Metodo para diagnosticar cancer.